Jason Glanz
Concepts (390)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Vaccines | 37 | 2026 | 389 | 7.890 |
Why?
| | Vaccination | 68 | 2026 | 1422 | 6.820 |
Why?
| | Drug Overdose | 20 | 2026 | 367 | 6.330 |
Why?
| | Immunization Schedule | 22 | 2025 | 187 | 5.480 |
Why?
| | Opioid-Related Disorders | 13 | 2026 | 576 | 4.040 |
Why?
| | Analgesics, Opioid | 24 | 2025 | 1131 | 3.410 |
Why?
| | Influenza Vaccines | 25 | 2024 | 529 | 2.850 |
Why?
| | Social Media | 6 | 2021 | 171 | 2.700 |
Why?
| | Influenza, Human | 18 | 2024 | 615 | 1.840 |
Why?
| | Parents | 12 | 2021 | 1401 | 1.720 |
Why?
| | Narcotic Antagonists | 6 | 2026 | 204 | 1.710 |
Why?
| | Patient Acceptance of Health Care | 8 | 2024 | 878 | 1.660 |
Why?
| | Consumer Health Information | 4 | 2020 | 49 | 1.650 |
Why?
| | Buprenorphine | 4 | 2026 | 181 | 1.620 |
Why?
| | Infant | 61 | 2026 | 10022 | 1.620 |
Why?
| | Cohort Studies | 39 | 2026 | 5935 | 1.440 |
Why?
| | Aluminum | 4 | 2026 | 43 | 1.440 |
Why?
| | Naltrexone | 2 | 2026 | 117 | 1.380 |
Why?
| | Vaccines, Inactivated | 9 | 2020 | 70 | 1.320 |
Why?
| | Health Knowledge, Attitudes, Practice | 14 | 2021 | 1409 | 1.300 |
Why?
| | Vaccination Coverage | 9 | 2025 | 102 | 1.260 |
Why?
| | Naloxone | 8 | 2022 | 132 | 1.240 |
Why?
| | Diphtheria-Tetanus-acellular Pertussis Vaccines | 8 | 2020 | 91 | 1.220 |
Why?
| | Child, Preschool | 55 | 2026 | 11774 | 1.210 |
Why?
| | Adverse Drug Reaction Reporting Systems | 8 | 2025 | 81 | 1.190 |
Why?
| | Opiate Substitution Treatment | 4 | 2026 | 174 | 1.190 |
Why?
| | Humans | 162 | 2026 | 144261 | 1.160 |
Why?
| | Mothers | 3 | 2020 | 774 | 1.130 |
Why?
| | Measles-Mumps-Rubella Vaccine | 9 | 2021 | 47 | 1.120 |
Why?
| | Chronic Pain | 5 | 2025 | 290 | 1.110 |
Why?
| | Safety | 5 | 2018 | 355 | 1.090 |
Why?
| | Pregnancy Complications, Infectious | 8 | 2024 | 422 | 1.090 |
Why?
| | Bias | 6 | 2021 | 201 | 1.050 |
Why?
| | Treatment Refusal | 6 | 2015 | 98 | 1.050 |
Why?
| | Internet | 5 | 2020 | 698 | 1.040 |
Why?
| | Models, Statistical | 6 | 2018 | 677 | 1.030 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 5 | 2020 | 257 | 1.010 |
Why?
| | Female | 103 | 2026 | 77976 | 0.990 |
Why?
| | Biometry | 2 | 2018 | 68 | 0.940 |
Why?
| | Insurance, Health | 2 | 2026 | 301 | 0.930 |
Why?
| | Male | 89 | 2026 | 72035 | 0.920 |
Why?
| | Rotavirus Vaccines | 4 | 2020 | 37 | 0.920 |
Why?
| | Whooping Cough | 5 | 2018 | 55 | 0.900 |
Why?
| | United States | 58 | 2026 | 15876 | 0.890 |
Why?
| | Colorado | 18 | 2025 | 4562 | 0.840 |
Why?
| | Incidence | 20 | 2026 | 2870 | 0.820 |
Why?
| | Patient Safety | 2 | 2020 | 347 | 0.820 |
Why?
| | Case-Control Studies | 23 | 2026 | 3592 | 0.800 |
Why?
| | Chickenpox Vaccine | 6 | 2021 | 75 | 0.790 |
Why?
| | Product Surveillance, Postmarketing | 9 | 2025 | 72 | 0.780 |
Why?
| | Patient Education as Topic | 4 | 2019 | 777 | 0.770 |
Why?
| | Measles | 3 | 2021 | 46 | 0.770 |
Why?
| | Electronic Health Records | 12 | 2024 | 1169 | 0.770 |
Why?
| | Retrospective Studies | 34 | 2024 | 17009 | 0.760 |
Why?
| | Pneumococcal Vaccines | 4 | 2025 | 130 | 0.760 |
Why?
| | Statistics as Topic | 2 | 2013 | 281 | 0.720 |
Why?
| | Adult | 52 | 2026 | 40262 | 0.710 |
Why?
| | Pharmacies | 1 | 2022 | 42 | 0.690 |
Why?
| | Pain Management | 1 | 2025 | 405 | 0.690 |
Why?
| | Pharmacoepidemiology | 1 | 2021 | 22 | 0.690 |
Why?
| | Vaccines, Attenuated | 4 | 2020 | 129 | 0.670 |
Why?
| | Child | 45 | 2022 | 22537 | 0.670 |
Why?
| | Vaccination Refusal | 2 | 2019 | 64 | 0.670 |
Why?
| | Decision Making | 6 | 2019 | 974 | 0.640 |
Why?
| | Antigens | 2 | 2021 | 347 | 0.630 |
Why?
| | Disease Outbreaks | 4 | 2024 | 422 | 0.620 |
Why?
| | Adjuvants, Immunologic | 2 | 2026 | 245 | 0.620 |
Why?
| | Antibodies, Viral | 1 | 2024 | 672 | 0.620 |
Why?
| | Reminder Systems | 1 | 2021 | 141 | 0.620 |
Why?
| | Risk Assessment | 13 | 2020 | 3637 | 0.610 |
Why?
| | Adolescent | 45 | 2025 | 22281 | 0.610 |
Why?
| | Middle Aged | 37 | 2026 | 35762 | 0.570 |
Why?
| | Odds Ratio | 6 | 2019 | 1072 | 0.570 |
Why?
| | Text Messaging | 1 | 2021 | 181 | 0.560 |
Why?
| | Morphine | 1 | 2019 | 168 | 0.540 |
Why?
| | Influenza A Virus, H1N1 Subtype | 4 | 2017 | 157 | 0.540 |
Why?
| | Benzodiazepines | 1 | 2019 | 165 | 0.530 |
Why?
| | Communicable Diseases | 1 | 2020 | 163 | 0.530 |
Why?
| | Abortion, Spontaneous | 4 | 2021 | 115 | 0.510 |
Why?
| | Databases, Factual | 4 | 2020 | 1484 | 0.510 |
Why?
| | Terminology as Topic | 1 | 2019 | 255 | 0.500 |
Why?
| | Databases, Pharmaceutical | 1 | 2016 | 5 | 0.480 |
Why?
| | Young Adult | 28 | 2026 | 13990 | 0.470 |
Why?
| | Professional-Family Relations | 2 | 2015 | 153 | 0.460 |
Why?
| | Patient Compliance | 2 | 2019 | 585 | 0.460 |
Why?
| | Gastrointestinal Diseases | 2 | 2018 | 216 | 0.450 |
Why?
| | Information Dissemination | 1 | 2017 | 220 | 0.450 |
Why?
| | Managed Care Programs | 2 | 2013 | 136 | 0.450 |
Why?
| | Prescription Drug Diversion | 1 | 2015 | 13 | 0.440 |
Why?
| | Proportional Hazards Models | 5 | 2021 | 1322 | 0.420 |
Why?
| | Fentanyl | 2 | 2025 | 126 | 0.420 |
Why?
| | Immunity, Humoral | 2 | 2026 | 120 | 0.410 |
Why?
| | Pregnancy | 17 | 2024 | 7180 | 0.410 |
Why?
| | Selection Bias | 1 | 2013 | 38 | 0.410 |
Why?
| | Housing | 1 | 2015 | 144 | 0.410 |
Why?
| | Diabetes Mellitus, Type 1 | 2 | 2021 | 3842 | 0.410 |
Why?
| | Sentinel Surveillance | 1 | 2013 | 46 | 0.400 |
Why?
| | Infant, Newborn | 16 | 2025 | 6424 | 0.400 |
Why?
| | Haemophilus Vaccines | 2 | 2025 | 29 | 0.390 |
Why?
| | Confidence Intervals | 5 | 2021 | 333 | 0.380 |
Why?
| | Public Health Surveillance | 4 | 2021 | 83 | 0.380 |
Why?
| | Myocarditis | 3 | 2022 | 102 | 0.380 |
Why?
| | Reproducibility of Results | 5 | 2020 | 3403 | 0.370 |
Why?
| | Logistic Models | 7 | 2020 | 2104 | 0.370 |
Why?
| | Biostatistics | 1 | 2012 | 19 | 0.360 |
Why?
| | Environmental Exposure | 2 | 2015 | 587 | 0.360 |
Why?
| | Purpura, Thrombocytopenic, Idiopathic | 2 | 2012 | 17 | 0.360 |
Why?
| | Health Services | 1 | 2013 | 114 | 0.360 |
Why?
| | Risk Factors | 16 | 2020 | 10699 | 0.360 |
Why?
| | Trust | 1 | 2013 | 151 | 0.350 |
Why?
| | Algorithms | 3 | 2018 | 1834 | 0.340 |
Why?
| | Practice Patterns, Physicians' | 6 | 2025 | 1347 | 0.340 |
Why?
| | Health Education | 1 | 2014 | 357 | 0.340 |
Why?
| | Aged | 20 | 2026 | 25850 | 0.340 |
Why?
| | Cause of Death | 4 | 2026 | 464 | 0.330 |
Why?
| | Epidemiologic Research Design | 1 | 2010 | 27 | 0.330 |
Why?
| | Asthma | 2 | 2022 | 1767 | 0.320 |
Why?
| | Pneumonia, Pneumococcal | 1 | 2010 | 47 | 0.320 |
Why?
| | Diphtheria-Tetanus-Pertussis Vaccine | 3 | 2018 | 27 | 0.320 |
Why?
| | Prescriptions | 2 | 2020 | 76 | 0.310 |
Why?
| | Hospitalization | 7 | 2020 | 2424 | 0.310 |
Why?
| | Eczema | 2 | 2022 | 66 | 0.310 |
Why?
| | Immunization | 4 | 2024 | 374 | 0.300 |
Why?
| | Pertussis Vaccine | 1 | 2009 | 24 | 0.300 |
Why?
| | Withholding Treatment | 2 | 2020 | 80 | 0.300 |
Why?
| | Chickenpox | 1 | 2010 | 81 | 0.290 |
Why?
| | Risk | 11 | 2021 | 909 | 0.290 |
Why?
| | Immunization Programs | 5 | 2024 | 193 | 0.290 |
Why?
| | Seizures | 4 | 2018 | 460 | 0.280 |
Why?
| | Seasons | 7 | 2024 | 556 | 0.280 |
Why?
| | Surveys and Questionnaires | 9 | 2024 | 6021 | 0.280 |
Why?
| | Models, Theoretical | 4 | 2020 | 582 | 0.280 |
Why?
| | Poisson Distribution | 4 | 2018 | 78 | 0.270 |
Why?
| | Predictive Value of Tests | 3 | 2021 | 2111 | 0.270 |
Why?
| | Clinical Trials as Topic | 2 | 2024 | 1050 | 0.260 |
Why?
| | Focus Groups | 3 | 2015 | 569 | 0.260 |
Why?
| | Seizures, Febrile | 3 | 2018 | 22 | 0.260 |
Why?
| | Epidemiologic Methods | 3 | 2019 | 89 | 0.260 |
Why?
| | Population Surveillance | 6 | 2013 | 483 | 0.250 |
Why?
| | Mortality | 3 | 2021 | 371 | 0.250 |
Why?
| | Data Mining | 2 | 2025 | 117 | 0.250 |
Why?
| | Database Management Systems | 2 | 2020 | 50 | 0.250 |
Why?
| | Sensitivity and Specificity | 3 | 2021 | 1983 | 0.240 |
Why?
| | Thrombocytopenia | 2 | 2022 | 205 | 0.240 |
Why?
| | Cross-Sectional Studies | 9 | 2025 | 5813 | 0.230 |
Why?
| | Time Factors | 10 | 2021 | 7155 | 0.230 |
Why?
| | Haemophilus influenzae type b | 1 | 2025 | 12 | 0.230 |
Why?
| | Research Design | 5 | 2024 | 1129 | 0.230 |
Why?
| | Age Factors | 7 | 2020 | 3313 | 0.230 |
Why?
| | Respiratory Syncytial Virus Vaccines | 1 | 2025 | 39 | 0.220 |
Why?
| | Haemophilus Infections | 1 | 2025 | 45 | 0.220 |
Why?
| | Transportation | 1 | 2025 | 54 | 0.220 |
Why?
| | Substance-Related Disorders | 4 | 2020 | 1054 | 0.210 |
Why?
| | Heroin Dependence | 2 | 2020 | 33 | 0.210 |
Why?
| | Computer Simulation | 4 | 2013 | 1025 | 0.210 |
Why?
| | California | 2 | 2024 | 469 | 0.210 |
Why?
| | Pneumococcal Infections | 1 | 2025 | 103 | 0.210 |
Why?
| | Methadone | 1 | 2025 | 110 | 0.210 |
Why?
| | Pandemics | 5 | 2024 | 1682 | 0.200 |
Why?
| | Respiratory Syncytial Virus Infections | 1 | 2025 | 136 | 0.200 |
Why?
| | Stillbirth | 2 | 2021 | 77 | 0.200 |
Why?
| | Health Services Research | 1 | 2006 | 394 | 0.200 |
Why?
| | Alcohol-Related Disorders | 1 | 2024 | 118 | 0.200 |
Why?
| | Intussusception | 2 | 2014 | 25 | 0.190 |
Why?
| | World Health Organization | 2 | 2002 | 103 | 0.190 |
Why?
| | Smallpox Vaccine | 1 | 2022 | 23 | 0.190 |
Why?
| | Morphine Derivatives | 1 | 2022 | 19 | 0.190 |
Why?
| | Qualitative Research | 4 | 2020 | 1659 | 0.190 |
Why?
| | Pericarditis | 1 | 2022 | 11 | 0.190 |
Why?
| | Multivariate Analysis | 5 | 2017 | 1533 | 0.190 |
Why?
| | Cataplexy | 1 | 2022 | 8 | 0.180 |
Why?
| | Bell Palsy | 1 | 2022 | 9 | 0.180 |
Why?
| | Anaphylaxis | 3 | 2021 | 102 | 0.180 |
Why?
| | Alcoholism | 4 | 2012 | 808 | 0.180 |
Why?
| | Gestational Age | 3 | 2021 | 975 | 0.180 |
Why?
| | Guillain-Barre Syndrome | 1 | 2022 | 22 | 0.180 |
Why?
| | Narcolepsy | 1 | 2022 | 25 | 0.180 |
Why?
| | Insurance | 1 | 2022 | 13 | 0.180 |
Why?
| | Drug Prescriptions | 2 | 2015 | 280 | 0.180 |
Why?
| | Urban Population | 1 | 2025 | 490 | 0.170 |
Why?
| | Herpes Zoster Vaccine | 1 | 2024 | 154 | 0.170 |
Why?
| | Delivery of Health Care, Integrated | 3 | 2021 | 297 | 0.170 |
Why?
| | Maternal Age | 1 | 2021 | 126 | 0.170 |
Why?
| | Epilepsy | 1 | 2026 | 375 | 0.170 |
Why?
| | Calibration | 1 | 2021 | 151 | 0.170 |
Why?
| | International Classification of Diseases | 2 | 2019 | 143 | 0.170 |
Why?
| | Premature Birth | 2 | 2024 | 380 | 0.170 |
Why?
| | Health Behavior | 2 | 2019 | 782 | 0.160 |
Why?
| | Medical Informatics | 2 | 2019 | 97 | 0.160 |
Why?
| | Data Interpretation, Statistical | 2 | 2021 | 371 | 0.160 |
Why?
| | Observational Studies as Topic | 2 | 2018 | 129 | 0.160 |
Why?
| | Heroin | 1 | 2020 | 29 | 0.160 |
Why?
| | RNA, Viral | 1 | 2024 | 687 | 0.160 |
Why?
| | Herpes Zoster | 1 | 2024 | 315 | 0.160 |
Why?
| | London | 1 | 2020 | 45 | 0.160 |
Why?
| | Rural Population | 1 | 2025 | 648 | 0.150 |
Why?
| | Bacterial Vaccines | 2 | 2023 | 63 | 0.150 |
Why?
| | Drug Dosage Calculations | 1 | 2019 | 27 | 0.150 |
Why?
| | Pharmacists | 1 | 2022 | 240 | 0.150 |
Why?
| | Aged, 80 and over | 8 | 2025 | 8243 | 0.150 |
Why?
| | Term Birth | 1 | 2018 | 25 | 0.140 |
Why?
| | Diphtheria-Tetanus Vaccine | 1 | 2018 | 5 | 0.140 |
Why?
| | Alcohol Drinking | 2 | 2002 | 812 | 0.140 |
Why?
| | Birth Weight | 1 | 2021 | 522 | 0.140 |
Why?
| | Congresses as Topic | 1 | 2020 | 221 | 0.140 |
Why?
| | Disease Susceptibility | 1 | 2020 | 346 | 0.140 |
Why?
| | Croup | 1 | 2018 | 19 | 0.140 |
Why?
| | Vaccines, Synthetic | 3 | 2024 | 138 | 0.140 |
Why?
| | Primary Health Care | 3 | 2018 | 1710 | 0.130 |
Why?
| | Monte Carlo Method | 1 | 2018 | 155 | 0.130 |
Why?
| | Rhinitis, Allergic | 1 | 2018 | 42 | 0.130 |
Why?
| | Delayed-Action Preparations | 1 | 2018 | 183 | 0.130 |
Why?
| | Follow-Up Studies | 4 | 2021 | 5389 | 0.130 |
Why?
| | Syncope | 1 | 2017 | 55 | 0.130 |
Why?
| | Diphtheria | 2 | 2018 | 21 | 0.130 |
Why?
| | Tetanus | 2 | 2018 | 26 | 0.130 |
Why?
| | Anemia, Sickle Cell | 2 | 2011 | 309 | 0.130 |
Why?
| | Measles Vaccine | 1 | 2017 | 18 | 0.130 |
Why?
| | Papillomavirus Vaccines | 1 | 2021 | 297 | 0.130 |
Why?
| | Infant Mortality | 1 | 2018 | 123 | 0.130 |
Why?
| | Papillomavirus Infections | 1 | 2021 | 345 | 0.120 |
Why?
| | Healthcare Disparities | 1 | 2023 | 725 | 0.120 |
Why?
| | Sex Factors | 2 | 2021 | 2096 | 0.120 |
Why?
| | Motivation | 1 | 2021 | 605 | 0.120 |
Why?
| | Drug Hypersensitivity | 1 | 2017 | 90 | 0.120 |
Why?
| | Immunization, Secondary | 3 | 2014 | 91 | 0.120 |
Why?
| | Drug Administration Schedule | 1 | 2018 | 778 | 0.120 |
Why?
| | Attitude to Health | 1 | 2019 | 434 | 0.120 |
Why?
| | Infectious Disease Transmission, Vertical | 1 | 2017 | 187 | 0.120 |
Why?
| | Food Hypersensitivity | 1 | 2018 | 164 | 0.120 |
Why?
| | Parenting | 1 | 2019 | 317 | 0.110 |
Why?
| | Cluster Analysis | 1 | 2017 | 519 | 0.110 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 382 | 0.110 |
Why?
| | Fever | 1 | 2017 | 311 | 0.110 |
Why?
| | Coronavirus Infections | 1 | 2020 | 377 | 0.110 |
Why?
| | Analysis of Variance | 4 | 2008 | 1304 | 0.110 |
Why?
| | Otitis Media | 1 | 2018 | 181 | 0.110 |
Why?
| | Age Distribution | 3 | 2017 | 397 | 0.110 |
Why?
| | Sex Distribution | 3 | 2017 | 380 | 0.110 |
Why?
| | Prognosis | 2 | 2018 | 4278 | 0.110 |
Why?
| | Heptavalent Pneumococcal Conjugate Vaccine | 2 | 2013 | 13 | 0.110 |
Why?
| | General Practice | 1 | 2015 | 32 | 0.110 |
Why?
| | Pilot Projects | 1 | 2020 | 1867 | 0.110 |
Why?
| | Chronic Disease | 2 | 2013 | 1812 | 0.110 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2019 | 2026 | 0.110 |
Why?
| | Telemedicine | 1 | 2024 | 940 | 0.110 |
Why?
| | Needle Sharing | 2 | 2005 | 10 | 0.110 |
Why?
| | Poliovirus Vaccine, Inactivated | 1 | 2014 | 27 | 0.100 |
Why?
| | Breast Feeding | 1 | 2018 | 448 | 0.100 |
Why?
| | Infant, Premature | 1 | 2018 | 611 | 0.100 |
Why?
| | Acute Disease | 2 | 2008 | 1028 | 0.100 |
Why?
| | User-Computer Interface | 1 | 2014 | 164 | 0.100 |
Why?
| | Mass Vaccination | 1 | 2013 | 18 | 0.100 |
Why?
| | Respiratory Tract Infections | 1 | 2018 | 396 | 0.100 |
Why?
| | Bacterial Capsules | 2 | 2025 | 33 | 0.100 |
Why?
| | Prehypertension | 1 | 2013 | 27 | 0.100 |
Why?
| | Physicians, Primary Care | 1 | 2015 | 206 | 0.100 |
Why?
| | Socioeconomic Factors | 4 | 2019 | 1312 | 0.100 |
Why?
| | Community Health Services | 1 | 2015 | 232 | 0.100 |
Why?
| | Venous Thromboembolism | 1 | 2017 | 324 | 0.100 |
Why?
| | Prisoners | 1 | 2015 | 143 | 0.100 |
Why?
| | Drug Utilization | 1 | 2013 | 166 | 0.090 |
Why?
| | Genes, MHC Class II | 1 | 2012 | 76 | 0.090 |
Why?
| | Viral Vaccines | 1 | 2014 | 107 | 0.090 |
Why?
| | Ambulatory Care | 2 | 2018 | 597 | 0.090 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2019 | 1705 | 0.090 |
Why?
| | Program Development | 1 | 2014 | 369 | 0.090 |
Why?
| | Substance Abuse, Intravenous | 2 | 2005 | 127 | 0.090 |
Why?
| | HIV Infections | 2 | 2024 | 3079 | 0.090 |
Why?
| | Community Health Centers | 1 | 2012 | 59 | 0.090 |
Why?
| | Pneumonia | 1 | 2017 | 630 | 0.090 |
Why?
| | Evidence-Based Medicine | 1 | 2015 | 729 | 0.090 |
Why?
| | Intensive Care Units | 1 | 2017 | 916 | 0.090 |
Why?
| | Prescription Drugs | 1 | 2013 | 110 | 0.090 |
Why?
| | Vaccines, Combined | 3 | 2018 | 49 | 0.080 |
Why?
| | Comparative Effectiveness Research | 1 | 2012 | 169 | 0.080 |
Why?
| | Hepatitis C | 2 | 2005 | 254 | 0.080 |
Why?
| | Prisons | 1 | 2012 | 84 | 0.080 |
Why?
| | Attitude of Health Personnel | 2 | 2016 | 1182 | 0.080 |
Why?
| | Prospective Studies | 5 | 2026 | 7970 | 0.080 |
Why?
| | Quality Assurance, Health Care | 1 | 2012 | 336 | 0.080 |
Why?
| | Anemia, Hemolytic | 1 | 2009 | 16 | 0.080 |
Why?
| | Hepatitis B Vaccines | 1 | 2009 | 43 | 0.070 |
Why?
| | Communication | 1 | 2015 | 961 | 0.070 |
Why?
| | Autistic Disorder | 1 | 2011 | 210 | 0.070 |
Why?
| | Self Report | 2 | 2024 | 863 | 0.070 |
Why?
| | Drug Evaluation | 1 | 2008 | 79 | 0.070 |
Why?
| | Purpura, Thrombocytopenic | 1 | 2008 | 5 | 0.070 |
Why?
| | Platelet Count | 1 | 2008 | 96 | 0.070 |
Why?
| | Splenectomy | 1 | 2008 | 65 | 0.070 |
Why?
| | Guideline Adherence | 1 | 2012 | 586 | 0.070 |
Why?
| | Communicable Disease Control | 1 | 2008 | 86 | 0.070 |
Why?
| | Linear Models | 2 | 2008 | 850 | 0.070 |
Why?
| | Clinical Competence | 1 | 2015 | 1241 | 0.060 |
Why?
| | Health Surveys | 1 | 2009 | 510 | 0.060 |
Why?
| | Blood Pressure | 1 | 2013 | 1759 | 0.060 |
Why?
| | Multicenter Studies as Topic | 1 | 2008 | 402 | 0.060 |
Why?
| | Antiviral Agents | 1 | 2012 | 767 | 0.060 |
Why?
| | Interrupted Time Series Analysis | 1 | 2025 | 74 | 0.060 |
Why?
| | Regression Analysis | 4 | 2015 | 998 | 0.060 |
Why?
| | Brain Ischemia | 1 | 2009 | 358 | 0.060 |
Why?
| | Respiratory Syncytial Virus, Human | 1 | 2025 | 81 | 0.050 |
Why?
| | Mass Screening | 1 | 2013 | 1332 | 0.050 |
Why?
| | Survival Analysis | 1 | 2008 | 1382 | 0.050 |
Why?
| | Hypertension | 1 | 2013 | 1254 | 0.050 |
Why?
| | Hepatitis B | 1 | 2005 | 66 | 0.050 |
Why?
| | Streptococcus pneumoniae | 1 | 2025 | 177 | 0.050 |
Why?
| | Severity of Illness Index | 2 | 2008 | 2917 | 0.050 |
Why?
| | Monoamine Oxidase | 1 | 2002 | 25 | 0.050 |
Why?
| | Adenylyl Cyclases | 1 | 2002 | 60 | 0.050 |
Why?
| | Registries | 2 | 2008 | 2382 | 0.050 |
Why?
| | Family Characteristics | 1 | 2023 | 196 | 0.040 |
Why?
| | Genetic Markers | 1 | 2002 | 331 | 0.040 |
Why?
| | Pregnancy Outcome | 1 | 2024 | 476 | 0.040 |
Why?
| | Chi-Square Distribution | 1 | 2002 | 527 | 0.040 |
Why?
| | Hypoxanthine Phosphoribosyltransferase | 1 | 2001 | 24 | 0.040 |
Why?
| | Aftercare | 1 | 2023 | 220 | 0.040 |
Why?
| | Radon | 1 | 2001 | 44 | 0.040 |
Why?
| | Cooperative Behavior | 2 | 2014 | 462 | 0.040 |
Why?
| | Herpesvirus 3, Human | 1 | 2024 | 336 | 0.040 |
Why?
| | Disease Progression | 1 | 2008 | 2840 | 0.040 |
Why?
| | Health Facilities | 1 | 2020 | 85 | 0.040 |
Why?
| | Policy | 1 | 2021 | 146 | 0.040 |
Why?
| | Stroke | 1 | 2009 | 1254 | 0.040 |
Why?
| | Intention | 1 | 2021 | 183 | 0.040 |
Why?
| | Health Personnel | 2 | 2015 | 742 | 0.040 |
Why?
| | Blood Platelets | 1 | 2002 | 399 | 0.040 |
Why?
| | History, 21st Century | 1 | 2019 | 219 | 0.040 |
Why?
| | Cellulitis | 1 | 2018 | 53 | 0.030 |
Why?
| | Cranial Nerve Diseases | 1 | 2018 | 43 | 0.030 |
Why?
| | Prevalence | 2 | 2021 | 2815 | 0.030 |
Why?
| | Hospitals | 1 | 2023 | 727 | 0.030 |
Why?
| | Health Status Disparities | 1 | 2021 | 321 | 0.030 |
Why?
| | Musculoskeletal Pain | 1 | 2018 | 43 | 0.030 |
Why?
| | Paralysis | 1 | 2018 | 67 | 0.030 |
Why?
| | Extremities | 1 | 2018 | 140 | 0.030 |
Why?
| | Brain Diseases | 1 | 2018 | 152 | 0.030 |
Why?
| | Respiratory Tract Diseases | 1 | 2018 | 175 | 0.030 |
Why?
| | Patient Discharge | 1 | 2023 | 977 | 0.030 |
Why?
| | Family Health | 1 | 2017 | 191 | 0.030 |
Why?
| | Venous Thrombosis | 1 | 2017 | 194 | 0.030 |
Why?
| | Psychometrics | 1 | 2019 | 730 | 0.030 |
Why?
| | Smoking | 1 | 2002 | 1468 | 0.030 |
Why?
| | Pulmonary Embolism | 1 | 2017 | 243 | 0.030 |
Why?
| | Longitudinal Studies | 2 | 2018 | 2926 | 0.030 |
Why?
| | Delivery of Health Care | 1 | 2022 | 940 | 0.030 |
Why?
| | Outpatients | 1 | 2018 | 439 | 0.030 |
Why?
| | RNA, Messenger | 1 | 2022 | 2829 | 0.030 |
Why?
| | Contraindications | 1 | 2014 | 91 | 0.030 |
Why?
| | Fetal Mortality | 1 | 2013 | 4 | 0.020 |
Why?
| | Vaccines, Acellular | 1 | 2012 | 3 | 0.020 |
Why?
| | Vaccines, Conjugate | 1 | 2013 | 60 | 0.020 |
Why?
| | Fetal Death | 1 | 2013 | 58 | 0.020 |
Why?
| | Comorbidity | 1 | 2017 | 1646 | 0.020 |
Why?
| | Off-Label Use | 1 | 2012 | 48 | 0.020 |
Why?
| | Mucocutaneous Lymph Node Syndrome | 1 | 2013 | 91 | 0.020 |
Why?
| | Rotavirus Infections | 1 | 2012 | 35 | 0.020 |
Why?
| | Hepatitis A Vaccines | 1 | 2012 | 20 | 0.020 |
Why?
| | Monitoring, Immunologic | 1 | 2011 | 23 | 0.020 |
Why?
| | Safety Management | 1 | 2011 | 121 | 0.020 |
Why?
| | Mutation | 1 | 2001 | 4085 | 0.020 |
Why?
| | Ultrasonography | 1 | 2013 | 768 | 0.020 |
Why?
| | Social Support | 1 | 2012 | 649 | 0.020 |
Why?
| | Family | 1 | 2012 | 679 | 0.020 |
Why?
| | Patient-Centered Care | 1 | 2012 | 540 | 0.020 |
Why?
| | Health Services Accessibility | 1 | 2015 | 1091 | 0.020 |
Why?
| | Emergency Medical Services | 1 | 2013 | 696 | 0.020 |
Why?
| | Mental Health | 1 | 2012 | 776 | 0.010 |
Why?
| | Neoplasms | 1 | 2001 | 2870 | 0.010 |
Why?
| | Syringes | 1 | 2005 | 49 | 0.010 |
Why?
| | Health Maintenance Organizations | 1 | 2004 | 104 | 0.010 |
Why?
| | Amphetamine-Related Disorders | 1 | 2005 | 47 | 0.010 |
Why?
| | Suicide | 1 | 2012 | 691 | 0.010 |
Why?
| | Methamphetamine | 1 | 2005 | 68 | 0.010 |
Why?
| | Genetic Predisposition to Disease | 1 | 2012 | 2359 | 0.010 |
Why?
| | Medical Record Linkage | 1 | 2004 | 68 | 0.010 |
Why?
| | Social Identification | 1 | 2005 | 72 | 0.010 |
Why?
| | Cocaine-Related Disorders | 1 | 2005 | 130 | 0.010 |
Why?
| | Social Environment | 1 | 2005 | 254 | 0.010 |
Why?
| | Illinois | 1 | 2003 | 45 | 0.010 |
Why?
| | Affinity Labels | 1 | 2002 | 25 | 0.010 |
Why?
| | Equipment Contamination | 1 | 2003 | 71 | 0.010 |
Why?
| | Cross-Over Studies | 1 | 2004 | 600 | 0.010 |
Why?
| | Statistics, Nonparametric | 1 | 2002 | 427 | 0.010 |
Why?
| | Enzyme Activation | 1 | 2002 | 765 | 0.010 |
Why?
| | Causality | 1 | 2001 | 126 | 0.010 |
Why?
| | Biomarkers | 2 | 2002 | 4254 | 0.010 |
Why?
| | Emergency Service, Hospital | 1 | 2012 | 2301 | 0.010 |
Why?
| | Marijuana Abuse | 1 | 2002 | 211 | 0.010 |
Why?
| | Protein Binding | 1 | 2002 | 2270 | 0.010 |
Why?
|
|
Glanz's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|